The possibility of using Mexidol in neuropediatrics

Authors:
N.N. ZAVADENKO, N.YU. SUVORINOVA, A.N. ZAVADENKO

FGAOU in Russian National Research Medical University named after N.I. Pirogov »Ministry of Health of Russia, Moscow, Russia

Place of publication:
S.S. KORSAKOV JOURNAL OF NEUROLOGY AND PSYCHIATRY, 2023, Vol. 123, No. 9, Issue 2

Abstract:
Mexidol (ethylmethylhydroxypyridine succinate) is a modern neurometabolic drug that is increasingly used in pediatric neurology. This article examines the results of recent studies confirming the positive effects of Mexidol pharmacotherapy in children with attention deficit hyperactivity disorder (ADHD), perinatal CNS lesions (hypoxic-ischemic encephalopathy) and their sequelae, neurological disorders and developmental delays after surgery for congenital heart defects, neuroinfections (meningitis, encephalitis), and post-traumatic epilepsy. Given Mexidol's unique multimodal action, it appears promising to expand its range of indications in pediatric neurology based on the results of new clinical trials, which will be organized in accordance with modern principles of evidence-based medicine.

Key words: Mexidol (ethylmethylhydroxypyridine succinate), children, treatment, hypoxic-ischemic encephalopathy, attention deficit hyperactivity disorder, neuropsychiatric retardation, meningitis, encephalitis, post-traumatic epilepsy.

Actual

Actual

THE INFORMATION IS INTENDED FOR HEALTHCARE AND PHARMACEUTICAL PROFESSIONALS. THIS INFORMATION IS NOT INTENDED AS A SUBSTITUTE FOR MEDICAL ADVICE.

Source of photos and images Shutterstock.com